CytoMed Therapeutics Limited Ordinary Shares (GDTC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CytoMed Therapeutics Limited Ordinary Shares (GDTC) has a cash flow conversion efficiency ratio of -0.299x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.05 Million) by net assets ($6.85 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CytoMed Therapeutics Limited Ordinary Sh defensive interval ratio to measure how many days the company can operate on defensive assets alone.
CytoMed Therapeutics Limited Ordinary Shares - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how CytoMed Therapeutics Limited Ordinary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
CytoMed Therapeutics Limited Ordinary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CytoMed Therapeutics Limited Ordinary Shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HEBEI YICHEN GRP H YC 05
F:HE2
|
N/A |
|
BTM Resources Bhd
KLSE:7188
|
-0.033x |
|
Par Drugs And Chemicals Limited
NSE:PAR
|
0.072x |
|
Tractial S.A.
PA:ALTRA
|
0.058x |
|
Waja Konsortium Bhd
KLSE:0102
|
-0.118x |
|
Personas Social Inc
V:PRSN
|
-0.185x |
|
Lanthanein Resources Ltd
AU:LNR
|
-0.019x |
|
NFL Biosciences SAS
PA:ALNFL
|
0.032x |
Annual Cash Flow Conversion Efficiency for CytoMed Therapeutics Limited Ordinary Shares (2019–2025)
The table below shows the annual cash flow conversion efficiency of CytoMed Therapeutics Limited Ordinary Shares from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see CytoMed Therapeutics Limited Ordinary Sh (GDTC) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.85 Million | $-3.70 Million | -0.539x | -80.04% |
| 2024-12-31 | $9.04 Million | $-2.71 Million | -0.300x | +4.59% |
| 2023-12-31 | $11.27 Million | $-3.54 Million | -0.314x | +86.83% |
| 2022-12-31 | $589.03K | $-1.40 Million | -2.385x | -260.85% |
| 2021-12-31 | $2.60 Million | $-1.72 Million | -0.661x | +65.61% |
| 2020-12-31 | $476.83K | $-916.39K | -1.922x | -480.90% |
| 2019-12-31 | $1.94 Million | $-640.52K | -0.331x | -- |
About CytoMed Therapeutics Limited Ordinary Shares
CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I… Read more